Report

May 6

Broughton Nicotine Services welcomes Paul Hardman as our new Head of Scientific Affairs

Broughton Nicotine Services is delighted to announce that Paul Hardman joins as Head of Scientific Affairs. This latest appointment further bolsters the company’s expansion plans.

We are delighted to welcome Paul Hardman to our team as he takes up the post of Head of Scientific Affairs.

 

Paul has extensive experience in inhaled product development across pharmaceutical, Electronic Nicotine Delivery Systems (ENDS) and consumer products and will help us expand our offer further for clients.

 

At Broughton Nicotine Services we have built a reputation for advancing a smoke-free future by helping ENDS companies bring non-combustible products to market – but we know we can do more. That is why we are currently expanding our full-service regulatory consultancy to cover new product categories including modern oral nicotine pouches and cannabis products.  

 

To progress these aims, we have made a series of senior level appointments, with Paul being the latest recruit in our expansion plan.

 

Paul will immediately undertake the task of growing the scientific affairs team further to enable the business to expand and continue to offer a premium consultancy experience for clients in the industry; and he is well placed to do so. He comes to Broughton from the role of scientific lead with Nerudia where he spent the previous five years designing the testing strategy for the chemistry of inhaled and oral next-generation nicotine products, from assessing a variety of prototypes at the early stages of development through to characterization of products for submission through the US Premarket Tobacco Product Application (PMTA) process. 

 

Earlier in his career Paul worked at a specialist pharmaceutical company where he gained experience of dry powder and metered dose inhaler development both for the treatment of local lung conditions and systemic absorption. He also has experience leading the quality control department in a multinational pharmaceutical company involved in the production of generic nicotine lozenges. 

Paul said: “I am passionate about the opportunity to work with multiple clients and really get to the heart of their products so that Broughton Nicotine Services can best serve these businesses by championing those points in their regulatory submissions.    

“My role will involve offering scientific and regulatory consultancy to clients and growing the team to enable us to deliver a highly effective offering as Broughton moves into new areas. I am eager to build on the success the business has already achieved.” 

 “By accelerating a smoke-free future, together with our clients, we can help realize global level tobacco harm reduction, and save the lives of the 1 billion people who continue to smoke today.”

 

Image: Paul Hardman

Paul Harman_20210423_111633

 

Need a consultation?

 

Can we help you?

Broughton Nicotine Services have deep CRO capabilities and an experienced team of scientific and regulatory professionals to manage full service global regulatory projects. Our knowledge of global regulatory pathways offers significant insights that can be incorporated into your project plans. Our mission is to accelerate safer nicotine-delivery products to market; advancing a smoke-free future.

Book a meeting with us today to discuss your requirements.

 

About the Author

Dr Nveed Chaudhary is Chief Regulatory Officer at Broughton Nicotine Services. He has over 15 years of experience in the Next Generation Nicotine Products (NGPs) industry. His educational background includes a Double Hons Degree in Pharmacology and Physiology from University College London and a PhD in Respiratory Molecular Medicine from the University of Southampton. His goal has always been to reduce the burden that lung disease has on patients, society, and public health. Early in his career he worked for the pharmaceutical industry and at Boehringer Ingelheim was the co-inventor of a novel drug for the treatment of idiopathic pulmonary fibrosis, nintedanib esylate, which received regulatory approval in 2014/15. Since 2006, Nveed had worked at three of the largest tobacco companies in the World, focused on the assessment and subsequent regulatory filing of NGPs, including e-cigarettes, heated tobacco products and modern oral nicotine products. His experience at British American Tobacco and Philip Morris International included leading multi-disciplinary, globally based teams on both pre-clinical and clinical assessment of NGPs. Later in his career at Philip Morris International, Nveed was Director of Strategic Communications, with a focus on Tobacco Harm Reduction (THR). In this role, as well as creating narratives around THR for regulatory and key opinion leader engagement, he also had a critical role in creating the narratives for the Premarket Tobacco Product Applications (PMTA) and Modified Risk Tobacco Product (MRTP) applications for IQOS. Most recently, Nveed directed the PMTA programme at Imperial Brands ensuring the timely submission of PMTA applications to support Imperial Brand’s range of deemed products in the USA. Nveed is a true pioneer for NGPs and has worked collaboratively with FDA in the submission of both PMTAs and MRTPs as well as having heavy involvement in PMTAs for both e-vapor and heated tobacco products. As a scientist and communicator, Nveed is passionate about story-telling and using scientific data to underpin the narratives of both regulatory submissions and tobacco harm reduction.